NEW YORK – Quanterix said Friday that it has entered an agreement with WuXi AppTec to open a laboratory at WuXi's Shanghai facility to offer Quanterix's Simoa technology.
Billerica, Massachusetts-based Quanterix said that the lab, which will open this year, will provide academic and industry researchers across the Asia-Pacific region with access to its Simoa technology and biomarker testing, development, and validation services.
"We’re excited to provide access to Simoa technology to the APAC region," Kevin Hrusovsky, Quanterix's chairman, president, and CEO said in a statement. "This partnership enables us to offer even deeper support to our customers in this region and is a testament to the passion and collaboration that is taking place across the world to eradicate disease and empower true precision health."
"Quanterix continues to demonstrate dominance in [biomarker research] with its Simoa platforms and assays," Steve Yank, Co-CEO at WuXi said. "We have a strong belief that this partnership, coupled with WuXi AppTec’s open-access enabling platform, especially in the clinical bioanalytical field, will provide comprehensive solutions to our customers in greater China and APAC to drive important advances in disease detection, treatment, and ultimately, prevention."
Financial and other terms of the agreement were not disclosed.